Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 11/20 | 0.63 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.62 |
| ▸ | CACNA2D1 | P54289 | 8/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.63 |
| ▸ | HTR1A | P08908 | 2/20 | 0.62 |
| ▸ | MLNR | O43193 | 1/20 | 0.62 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.62 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.62 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL3312526 | 1.00 | CACNA2D1 (0.67) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Oxalic Acid SCHEMBL1535363 | 1.00 | CACNA2D1 (0.67) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Succinic Acid SCHEMBL5530810 | 0.94 | CACNA2D1 (0.65) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Succinic Acid SCHEMBL5512390 | 0.94 | CACNA2D1 (0.65) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL3592 | 0.93 | CACNA2D1 (0.76) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL29420217 | 0.93 | CACNA2D1 (0.76) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL521869 | 0.93 | CACNA2D1 (0.76) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL12342733 | 0.93 | CACNA2D1 (0.76) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL521176 | 0.93 | CACNA2D1 (0.76) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Maleic Acid SCHEMBL4621200 | 0.93 | CACNA2D1 (0.64) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2016066-A2 | PROCESS FOR PREPARING DULOXETINE | Dr. Reddy's Laboratories Ltd. (IN) | 2009-01-21 | — | — | EP | claimed |
| WO-2007134168-A2 | PROCESS FOR PREPARING DULOXETINE | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-11-22 | — | — | WO | claimed |
| EP-2558455-B1 | SYNTHESIS OF DULOXETINE AND/OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | KRKA D D NOVO MESTO (SI) | 2017-08-09 | — | — | EP | disclosed |
| EP-2558455-A1 | SYNTHESIS OF DULOXETINE AND/OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | KRKA, D.D., Novo Mesto (SI) | 2013-02-20 | — | — | EP | disclosed |
| US-8269023-B2 | Process for preparation of duloxetine hydrochloride | LUPIN LTD. (IN) | 2012-09-18 | — | — | US | disclosed |
| WO-2011128370-A1 | SYNTHESIS OF DULOXETINE AND/OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | KRKA, D.D., NOVO MESTO (SI) | 2011-10-20 | — | — | WO | disclosed |
| US-20110150942-A1 | GASTRO-RESISTANT PHARMACEUTICAL ORAL COMPOSITIONS COMPRISING DULOXETINE OR ITS PHARMACEUTICALLY ACCEPTABLE DERIVATIVES | KRKA, D.D. NOVO MESTO (SI) | 2011-06-23 | — | — | US | disclosed |
| US-20100267968-A1 | METHOD FOR THE PREPARATION OF DULOXETINE HYDROCHLORIDE | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2010-10-21 | — | — | US | disclosed |
| EP-1857451-B1 | A process for the preparation of an intermediate useful for the asymmetric synthesis of (+)duloxetine | FIDIA FARMACEUTICI (IT) | 2010-07-21 | — | — | EP | disclosed |
| US-20100105925-A1 | NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE | LUPIN LIMITED (IN) | 2010-04-29 | — | — | US | disclosed |
| EP-2133072-A1 | Gastro-resistant pharmaceutical oral compositions comprising duloxetine or its pharmaceutically acceptable derivatives | KRKA, D.D., Novo Mesto (SI) | 2009-12-16 | — | — | EP | disclosed |
| US-20060270860-A1 | Crystal forms of (S)-(+)-N,N-Dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine oxalate and the preparation thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2006-11-30 | — | — | US | disclosed |
| US-20060194869-A1 | Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2006-08-31 | — | — | US | disclosed |
| WO-2006071868-A2 | PROCESS FOR PREPARING PHARMACEUTICALLY ACCEPTABLE SALTS OF DULOXETINE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006027798-A2 | A PROCESS FOR PREPARATION OF AN ANTIDEPRESSANT COMPOUND | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2006-03-16 | — | — | WO | disclosed |
| EP-0457559-A2 | Chiral synthesis of 1-aryl-3-aminopropan-1-ols | ELI LILLY AND COMPANY (US) | 1991-11-21 | — | — | EP | disclosed |
| US-5023269-A | 3-aryloxy-3-substituted propanamines | ELI LILLY AND COMPANY (US) | 1991-06-11 | — | — | US | disclosed |
| EP-0273658-B1 | 3-ARYLOXY-3-SUBSTITUTED PROPANAMINES | ELI LILLY AND COMPANY (US) | 1990-10-31 | — | — | EP | disclosed |
| US-4956388-A | ANTIDEPRESSANTS, ANTIANXIETY, TREATMENT OF OBESITY, ADDICTION TO SMOKING AND ALCOHOL | ELI LILLY AND COMPANY (US) | 1990-09-11 | — | — | US | disclosed |
| EP-0273658-A1 | 3-Aryloxy-3-substituted propanamines | ELI LILLY AND COMPANY (US) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194869-A1 | Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof | UGT1A4, UGT2B7, UGT1A8 | SLC6A4 8/4885OPRM1 845/4885CACNA2D1 566/4885 |
| US-20110150942-A1 | GASTRO-RESISTANT PHARMACEUTICAL ORAL COMPOSITIONS COMPRISING DULOXETINE OR ITS PHARMACEUTICALLY ACCEPTABLE DERIVATIVES | HTR5A, OPRM1, CYP3A5 | SLC6A4 41/4885OPRM1 2/4885CACNA2D1 4098/4885 |
| US-20100105925-A1 | NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE | MAOA, SLC6A3, PNMT | SLC6A4 16/4885OPRM1 9/4885CACNA2D1 741/4885 |
| US-20100267968-A1 | METHOD FOR THE PREPARATION OF DULOXETINE HYDROCHLORIDE | PNMT, HTR3A, TPH1 | SLC6A4 37/4885OPRM1 65/4885CACNA2D1 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.